CoChat

Suboptimal Inhibition of Platelet Cyclooxygenase-1 by Aspirin in Metabolic Syndrome

Open access
Smith, James P., Haddad, Elias V., Taylor, Mary B., Oram, Denise, Blakemore, Dana, Chen, Qingxia, Boutaud, Olivier, Oates, John A. · 2012 · Hypertension
Cited by 58

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Interindividual variation in the ability of aspirin to inhibit platelet cyclooxygenase-1 (COX-1) could account for some on-treatment cardiovascular events. Here, we sought to determine whether there are clinical phenotypes that are associated with a suboptimal pharmacological effect of aspirin. In a prospective, 2-week study, we evaluated the effect of aspirin (81 mg) on platelet COX-1 in 135 patients with stable coronary artery disease by measuring serum thromboxane B 2 (sTxB 2 ) as an indicator of inhibition of platelet COX-1. A nested randomized study compared enteric-coated with immediate-release formulations of aspirin. We found that sTxB 2 was systematically higher among the 83 patients with metabolic syndrome than among the 52 patients without (median: 4.0 versus 3.02 ng/mL; P =0.013). Twelve patients (14%) with metabolic syndrome, but none without metabolic syndrome, had sTxB 2 levels consistent with inadequate inhibition of COX (sTxB 2 ≥13 ng/mL). In linear regression models, metabolic syndrome (but none of its individual components) significantly associated with higher levels of log-transformed sTxB 2 ( P =0.006). Higher levels of sTxB 2 associated with greater residual platelet function measured by aggregometry-based methods. Among the randomized subset, sTxB 2 levels were systematically higher among patients receiving enteric-coated aspirin. Last, urinary 11-dehydro thromboxane B 2 did not correlate with sTxB 2 , suggesting that the former should not be used to quantitate aspirin's pharmacological effect on platelets. In conclusion, metabolic syndrome, which places patients at high risk for thrombotic cardiovascular events, strongly and uniquely associates with less effective inhibition of platelet COX-1 by aspirin.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/hypertensionaha.111.181404

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 58

Metadata

Authors
Smith, J. P., Haddad, E. V., Taylor, M. B., Oram, D., Blakemore, D., Chen, Q., Boutaud, O., & Oates, J. A.
Venue
Hypertension
Published
2012-03
Volume
59
Issue
3
Pages
719-725
ISSN
  • 0194-911X (ISSN-L)
  • 1524-4563
OpenAlex
W2149678323
Cited by
58
References
5
FWCI
4.60
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Suboptimal Inhibition of Platelet Cyclooxygenase-1 by Aspirin in Metabolic Syndrome. https://app.cochat.ai/papers/10.1161/hypertensionaha.111.181404
The paper
Smith, J. P., Haddad, E. V., Taylor, M. B., Oram, D., Blakemore, D., Chen, Q., Boutaud, O., & Oates, J. A. (2012). Suboptimal Inhibition of Platelet Cyclooxygenase-1 by Aspirin in Metabolic Syndrome. Hypertension. https://doi.org/10.1161/hypertensionaha.111.181404

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.